多发性骨髓瘤动物模型中硼替佐米疗效的[18F]FDG与[64Cu]Cu-LLP2A PET定量评估
该研究在多发性骨髓瘤(MM)播散性小鼠模型中,比较了[18F]FDG与靶向VLA4的[64Cu]Cu-LLP2A PET在硼替佐米治疗后定量评估疗效的能力。结果显示[64Cu]Cu-LLP2A PET能更早检测到治疗相关变化,是有前景的疗效评估示踪剂。
要点
- VLA4在MM细胞高表达,[64Cu]Cu-LLP2A靶向VLA4用于PET显像。
- 硼替佐米治疗后,[64Cu]Cu-LLP2A在脊柱和股骨的SUVmean显著低于未治疗组。
- [18F]FDG PET检测治疗相关变化的时间点较[64Cu]Cu-LLP2A晚。
核心结论
- [64Cu]Cu-LLP2A是有前景的示踪剂,可及时在体评估播散性MM模型中的治疗反应。
研究设计与样本
- 研究将表达荧光素酶和绿色荧光蛋白的人MM细胞MM.1S-CG与U266-CG经静脉注射入NOD-SCID gamma小鼠,用生物发光成像监测肿瘤进展。
- 治疗组腹腔注射硼替佐米(1 mg/kg,每周两次),所有队列(治疗、未治疗及无肿瘤)纵向行[18F]FDG(7.4-8.0 MBq)与[64Cu]Cu-LLP2A(2-3 MBq;摩尔活度44.14 ± 1.40 MBq/nmol)PET显像。
主要发现
- 流式细胞术证实U266细胞CD49d高表达(> 99%),MM.1S细胞中等表达(约52%)。
- 生物发光成像显示治疗小鼠全身总通量下降。
- MM.1S-CG未治疗与治疗小鼠相比,肿瘤接种后第4周[64Cu]Cu-LLP2A在脊柱(SUVmean 0.58 vs 0.31,p < 0.01)和股骨(0.72 vs 0.39,p < 0.05)的摄取显著更高。
- U266-CG未治疗小鼠在治疗后3周[64Cu]Cu-LLP2A的SUVmean摄取较治疗小鼠高四倍。
- 与[64Cu]Cu-LLP2A相比,[18F]FDG PET在更晚的时间点才检测到治疗相关变化。
关键数值与推荐
- 硼替佐米剂量为1 mg/kg,每周两次,腹腔注射。
- [18F]FDG给药活度为7.4-8.0 MBq;[64Cu]Cu-LLP2A给药活度为2-3 MBq,摩尔活度44.14 ± 1.40 MBq/nmol。
- MM.1S-CG模型第4周[64Cu]Cu-LLP2A脊柱SUVmean未治疗vs治疗为0.58 vs 0.31(p < 0.01),股骨为0.72 vs 0.39(p < 0.05)。
- U266-CG模型治疗后3周未治疗组[64Cu]Cu-LLP2A的SUVmean摄取为治疗组的四倍。
临床怎么用
- 在MM治疗反应评估中,靶向VLA4的[64Cu]Cu-LLP2A PET可能比[18F]FDG PET更早显示治疗相关变化。
- VLA4表达水平可能影响[64Cu]Cu-LLP2A PET的显像结果,需结合肿瘤VLA4表达状态解读。
局限性
- 研究为动物模型(NOD-SCID gamma小鼠)研究,结论需进一步临床验证。
- 未报告[64Cu]Cu-LLP2A与[18F]FDG PET在更长时间点的系统比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple myeloma (MM) is a disease of cancerous plasma cells in the bone marrow. Imaging-based timely determination of therapeutic response is critical for improving outcomes in MM patients. Very late antigen-4 (VLA4, CD49d/CD29) is overexpressed in MM cells. Here, we evaluated [18F]FDG and VLA4 targeted [64Cu]Cu-LLP2A for quantitative PET imaging in disseminated MM models of variable VLA4 expression, following bortezomib therapy. METHODS: In vitro and ex vivo VLA4 expression was evaluated by flow cytometry. Human MM cells, MM.1S-CG and U266-CG (C: luciferase and G: green fluorescent protein), were injected intravenously in NOD-SCID gamma mice. Tumor progression was monitored by bioluminescence imaging (BLI). Treatment group received bortezomib (1 mg/kg, twice/week) intraperitoneally. All cohorts (treated, untreated and no tumor) were longitudinally imaged with [18F]FDG (7.4-8.0 MBq) and [64Cu]Cu-LLP2A (2-3 MBq; Molar Activity: 44.14 ± 1.40 MBq/nmol) PET, respectively. RESULTS: Flow cytometry confirmed high expression of CD49d in U266 cells (> 99%) and moderate expression in MM.1S cells (~ 52%). BLI showed decrease in total body flux in treated mice. In MM.1S-CG untreated versus treated mice, [64Cu]Cu-LLP2A localized with a significantly higher SUVmean in spine (0.58 versus 0.31, p < 0.01) and femur (0.72 versus 0.39, p < 0.05) at week 4 post-tumor inoculation. There was a four-fold higher uptake of [64Cu]Cu-LLP2A (SUVmean) in untreated U266-CG mice compared to treated mice at 3 weeks post-treatment. Compared to [64Cu]Cu-LLP2A, [18F]FDG PET detected treatment-related changes at later time points. CONCLUSION: [64Cu]Cu-LLP2A is a promising tracer for timely in vivo assessment of therapeutic response in disseminated models of MM.
引用
- Ghai A, Fettig N, Fontana F, et al. In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [18F]FDG and [64Cu]Cu-LLP2A PET. EJNMMI Res. 2021. PMID: 34586539. doi:10.1186/s13550-021-00840-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。